Incruse Ellipta

Umeclidinium bromide, the active ingredient in Incruse Ellipta, is a long‑acting muscarinic antagonist presented as a dry powder inhaler for inhalation use. It provides bronchodilation for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients, helping to improve lung function and reduce the frequency of exacerbations.

GNH USA supplies Incruse Ellipta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Incruse Ellipta, a long‑acting muscarinic antagonist, is indicated for maintenance treatment of chronic obstructive pulmonary disease (COPD).

- COPD (moderate to severe): reduces symptoms and frequency of exacerbations. - COPD (stable disease): maintains lung function and improves airflow. - COPD (maintenance therapy): enhances exercise tolerance and quality of life. - COPD (daily symptoms): provides sustained bronchodilation throughout the day. - COPD (exacerbation prevention): lowers risk of hospitalisation. - COPD (airflow limitation): improves FEV1 values.

Common Side Effects: - Cough - Dry mouth - Throat irritation - Headache

Serious or Rare Side Effects: - Paradoxical bronchospasm - Allergic reaction (rash, angioedema) - Urinary retention

Before initiating therapy, consider the following precautions: - Assess lung function: obtain baseline spirometry. - Monitor for worsening symptoms: advise patients to seek medical attention if breathlessness increases. - Use with caution in narrow‑angle glaucoma: may elevate intra‑ocular pressure. - Use with caution in patients with urinary retention: monitor urinary output. - Avoid in individuals with known hypersensitivity to umeclidinium or excipients. - Store at ambient temperature: keep inhaler in original packaging, protect from moisture and heat.

Incruse Ellipta may interact with other medicines as follows:

Major Interactions (Avoid): - Concomitant use with other long‑acting muscarinic antagonists may increase anticholinergic burden. - Co‑administration with potent anticholinergic agents (e.g., atropine) can exacerbate side‑effects.

Moderate Interactions (Monitor Closely): - Beta‑agonists may produce additive bronchodilation; monitor for tachycardia. - Theophylline may increase risk of nausea or arrhythmia when combined. - Inhaled corticosteroids may raise local irritation; observe airway symptoms.